These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30691369)

  • 21. The use of novel agents in multiple myeloma patients with hepatic impairment.
    Stansfield LC; Gonsalves WI; Buadi FK
    Future Oncol; 2015; 11(3):501-10. PubMed ID: 25675129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
    Bianchi G; Ghobrial IM
    Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three new drugs for multiple myeloma.
    Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
    [No Abstract]   [Full Text] [Related]  

  • 25. The pharmacologic management of multiple myeloma in older adults.
    Dempsey JL; Johns A; Rosko AE; Lazarus HM
    Expert Opin Pharmacother; 2019 May; 20(7):887-902. PubMed ID: 30785310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How is patient care for multiple myeloma advancing?
    Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
    Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New drugs in the treatment of multiple myeloma].
    Oriol A; Motlló C
    Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.
    Podar K; Pecherstorfer M
    Expert Opin Pharmacother; 2017 Aug; 18(11):1061-1079. PubMed ID: 28604120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
    Lonial S; Durie B; Palumbo A; San-Miguel J
    Leukemia; 2016 Mar; 30(3):526-35. PubMed ID: 26265184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
    Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P
    Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovations in treatment and response evaluation in multiple myeloma.
    Wester R; Sonneveld P
    Haematologica; 2016 May; 101(5):518-20. PubMed ID: 27132277
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel agents in CNS myeloma treatment.
    Gozzetti A; Cerase A
    Cent Nerv Syst Agents Med Chem; 2014; 14(1):23-7. PubMed ID: 25134940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
    Salvini M; Bonello F; Boccadoro M; Larocca A
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies targeting the ubiquitin proteasome system in cancer.
    Weathington NM; Mallampalli RK
    J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunomodulatory Agents and Proteasome Inhibitors in the Treatment of Multiple Myeloma.
    Noonan K; Colson K
    Semin Oncol Nurs; 2017 Aug; 33(3):279-291. PubMed ID: 28666621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
    Jelinek T; Hajek R
    Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular targeting agents for multiple myeloma].
    Fujii S; Abe M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.